公开(公告)号：US20210276967A1

公开(公告)日：2021-09-09

申请号：US17261223

申请日：2019-07-19

申请人： OSPEDALE SAN RAFFAELE S.R.L. ,  IRBM S.P.A. ,  PROMIDIS S.R.L. ,  ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM

发明人： Raffaele DE FRANCESCO ,  Adolfo PRANDI ,  Pietro RANDAZZO ,  Lorena DONNICI ,  Luca GUIDOTTI ,  Matteo IANNACONE ,  Romano DI FABIO ,  Vincenzo SUMMA ,  Leda Ivanova BENCHEVA ,  Marilenia DE MATTEO ,  Luca FERRANTE

IPC分类号： C07D305/08 ,  A61K45/06 ,  C07D207/48 ,  C07D213/42 ,  C07D205/04 ,  C07D213/73 ,  C07D211/96 ,  C07C311/16

摘要： The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

公开(公告)号：US09676825B2

公开(公告)日：2017-06-13

申请号：US14440443

申请日：2013-10-28

申请人： Centro de Ingeniería Genética y Biotecnología

发明人： Santiago Dueñas Carrera ,  Daylen Aguilar Noriega ,  Yalena Amador Cañizares ,  Liz Alvarez-Lajonchere Ponce de León ,  Gillian Martínez Donato ,  Sonia Gonzalez Blanco

IPC分类号： A61K39/12 ,  C12N7/00 ,  C07K14/005 ,  A61K39/29 ,  C07K7/08 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/53 ,  A61K2039/55505 ,  C07K7/08 ,  C12N7/00 ,  C12N2770/24234 ,  C12N2770/24271

摘要： The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV) comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially formed specific epitopes for auxiliary T helper lymphocytes. The chimeric antigens and the resulting vaccine compositions are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components.

公开(公告)号：US09505830B2

公开(公告)日：2016-11-29

申请号：US13976060

申请日：2011-12-26

申请人： Humberto Lamdan Ordas ,  Jorge Victor Gavilondo Cowley ,  Marta Ayala Avila ,  Yasmiana Muñoz Pozo ,  Amaury Pupo Meriño ,  Gertrudis Rojas Dorantes ,  Lincidio Perez Sanchez

发明人： Humberto Lamdan Ordas ,  Jorge Victor Gavilondo Cowley ,  Marta Ayala Avila ,  Yasmiana Muñoz Pozo ,  Amaury Pupo Meriño ,  Gertrudis Rojas Dorantes ,  Lincidio Perez Sanchez

IPC分类号： C07K16/22 ,  A61K39/395 ,  A61K51/10 ,  A61K39/00

CPC分类号： C07K16/22 ,  A61K51/1021 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with an increase in vasculature, such as age-related macular degeneration, cancer, and others.

摘要翻译： 本发明揭示识别人血管内皮生长因子A（VEGF-A）的人重组抗体，阻断其与VEGFR2受体的相互作用，并且干扰其在体内的增殖作用和促血管生成作用。 抗体鉴定了与之前报道的任何其它VEGF不同的人VEGF-A上的表位，并且通过将一个免疫球蛋白轻链可变区与其他三个重链可变区组合获得。 通过人免疫球蛋白可变区诱变获得抗体，可用于与血管系统增加相关的病理实体的免疫治疗，如年龄相关性黄斑变性，癌症等。

公开(公告)号：US09364524B2

公开(公告)日：2016-06-14

申请号：US14662482

申请日：2015-03-19

申请人： Centro de Ingenieria Genetica Y Biotecnologia

发明人： Jesus Arturo Junco Barranco ,  Osvaldo Reyes Acosta ,  Eddy Emilio Bover Fuentes ,  Franklin Fuentes Aguilar ,  Eulogio Pimentel Vazquez ,  Roberto Basulto Baker ,  Gerardo Enrique Guillen Nieto ,  Yovisleidys Lopez Saez ,  Hilda Elisa Garay Perez ,  Lesvia Calzada Aguilera ,  Maria Castro Santana ,  Niurka Oneysi Arteaga More ,  Luis Alberto Aguero Barrocal

IPC分类号： A61K39/00 ,  A61K38/09 ,  A61K47/48

CPC分类号： A61K39/0011 ,  A61K38/09 ,  A61K39/0006 ,  A61K47/48261 ,  A61K47/4833 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/585 ,  A61K2039/6037 ,  A61K2300/00

摘要： A pharmaceutical composition using natural gonadotropin—releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors.

摘要翻译： 使用天然促性腺激素释放激素（GnRH）和/或其一些模拟肽的药物组合物，其不明显地被其氨基或羧基末端与载体分子结合; 在一种情况下其羧基末端，另一种情况下由氨基末端极端，从而引发对内源GnRH激素的更快更有效的免疫应答。 这最终导致消化GnRH，从而导致流GnRH / LH-FSH /睾酮（雌激素）中涉及的其他激素的消融。 该制剂的优点在于促进免疫系统暴露于更多数量的GnRH或其模拟物的表位，从而最小化载体产生的空间位阻。 本发明直接应用于经济兴趣的宠物和动物的阉割，控制人的生育能力以及治疗激素敏感性肿瘤，如前列腺，乳腺，卵巢， 睾丸，垂体，唾液腺等多种人体肿瘤。

公开(公告)号：US09119830B2

公开(公告)日：2015-09-01

申请号：US13989921

申请日：2011-11-30

申请人： Mario Pablo Estrada Garcia ,  Juna Maria Lugo Gonzalez ,  Yamila Carpio Gonzalez ,  Carolina Tafalla Piñeiro

发明人： Mario Pablo Estrada Garcia ,  Juna Maria Lugo Gonzalez ,  Yamila Carpio Gonzalez ,  Carolina Tafalla Piñeiro

IPC分类号： A61K9/08 ,  A61K31/7056 ,  A61K38/22 ,  A61K9/00 ,  A61K9/51

CPC分类号： A61K38/2278 ,  A61K9/0019 ,  A61K9/0056 ,  A61K9/08 ,  A61K9/5153 ,  A61K31/7056 ,  A61K38/22 ,  A61K2300/00

摘要： The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR.

摘要翻译： 本发明涉及垂体腺苷酸环化酶活化多肽（PACAP）用于治疗由水生生物体中的病毒引起的病毒性疾病和感染性疾病的用途。 单独或与抗病毒分子组合的PACAP通过口服，注射或浸浴进行口服，通过增加感染病毒的鱼或甲壳类动物的存活来证明其有效性。 此外，观察到与感染和未处理的生物体相比，被处理的生物体保持或增加其重量。 含PACAP或含PACAP的组合降低了病毒感染的组织和器官中的病毒载量，如通过RT-PCR确定的。

公开(公告)号：US09055744B2

公开(公告)日：2015-06-16

申请号：US13865437

申请日：2013-04-18

申请人： Centro de Ingenieria Genetica y Biotecnologia

发明人： Orlando Borras Hidalgo ,  Roxana Caridad Portieles Alvarez ,  Merardo Pujol Ferrer ,  Gil Alberto Enriquez Obregon ,  Ernesto Manuel Gonzalez Ramos ,  Camilo Ayra Pardo ,  Carlos Guillermo Borroto Nordelo

IPC分类号： C12N15/82 ,  A01N37/18 ,  C07K14/415

CPC分类号： A01N37/18 ,  C07K14/415 ,  C12N15/8279 ,  C12N15/8282

摘要： The present invention reveals a nucleic acid sequence from Nicotiana megalosiphon encoding for an anti-pathogenic protein. The invention comprises the use of this nucleic acid molecule in transgenic plants of agricultural interest to confer resistance to pathogens. The invention also includes a bioproduct that comprises this anti-pathogenic protein to control plant pathogen agents.

摘要翻译： 本发明揭示了编码抗病原性蛋白质的烟草巨乳的核酸序列。 本发明包括在农业感兴趣的转基因植物中使用该核酸分子来赋予对病原体的抗性。 本发明还包括一种生物产物，其包含该抗病原性蛋白质以控制植物病原体。

公开(公告)号：US08962914B2

公开(公告)日：2015-02-24

申请号：US14261775

申请日：2014-04-25

申请人： TMG—Tropical Melhoramento E Genetica LTDA.

发明人： Arlindo Harada ,  Eberson Sanches Calvo ,  Romeu Afonso de Souza Kiihl ,  Alexandre Garcia

IPC分类号： A01H1/04 ,  A01H1/02 ,  A01H5/10 ,  C12Q1/68

CPC分类号： C12Q1/6895 ,  A01H1/04 ,  A01H5/10 ,  C12Q2600/156

摘要： The present invention relates to screening methods for rust resistance or tolerance, in particular, Asian soybean rust (ASR—Phakopsora pachyrhizi). In addition, the present invention relates to the use of molecular markers for the Glycine genus, in particular, for the Glycine max species. The present invention further relates to a method for identifying loci with quantitative and/or qualitative traits associated with rust resistance or tolerance in plants by means of molecular markers. Said markers can be used for assisted screening in improvement programs directed to selecting disease-resistant or -tolerant plants. The present invention also relates to gene pyramiding related to rust resistance. The markers of the present invention are also useful for the positional cloning of rust-resistant or -tolerant genes. Also disclosed are a method for obtaining disease-resistant or -tolerant cultivars, a process for obtaining a plant population and a method for controlling diseases in a plant population. Another object of the present invention is the use of species from the Glycine genus as a source of resistance for obtaining ASR-resistant or tolerant cultivars.

摘要翻译： 本发明涉及耐锈性或耐受性的筛选方法，特别是亚洲大豆锈病（ASR- Phakopsora pachyrhizi）。 此外，本发明涉及分子标记用于甘氨酸属的用途，尤其涉及大豆种类。 本发明还涉及通过分子标记鉴定具有与植物抗锈性或耐受性有关的定量和/或定性性状的基因座的方法。 所述标记物可用于辅助筛选，用于选择抗病性或耐受性植物的改良方案。 本发明还涉及与抗锈性相关的基因金字塔。 本发明的标记物也可用于防锈或耐受基因的定位克隆。 还公开了获得抗病性或耐性品种的方法，获得植物群体的方法和控制植物群体中的疾病的方法。 本发明的另一个目的是使用来自甘氨酸属的物质作为获得抗ASR抗性或耐受品种的抗性来源。

公开(公告)号：US08852601B2

公开(公告)日：2014-10-07

申请号：US10501697

申请日：2003-01-22

申请人： Mario Pablo Estrada Garcia ,  Rebeca Martinez Rodriguez ,  Amilcar Arenal Cruz ,  Rafael Marcos Pimentel Pérez ,  Antonio Morales Rojas ,  Eulogio Pimentel Vázquez ,  Alexander Espinosa Vázquez ,  Carmen Aday Garcia Molina ,  Edenaida Cabrera González ,  Mirta Vinjoy Campa ,  Sergio Toledo Pérez ,  Olimpia Carrillo Famés ,  Claudina Zaldivar Muñoz

发明人： Mario Pablo Estrada Garcia ,  Rebeca Martinez Rodriguez ,  Amilcar Arenal Cruz ,  Rafael Marcos Pimentel Pérez ,  Antonio Morales Rojas ,  Eulogio Pimentel Vázquez ,  Alexander Espinosa Vázquez ,  Carmen Aday Garcia Molina ,  Edenaida Cabrera González ,  Mirta Vinjoy Campa ,  Sergio Toledo Pérez ,  Olimpia Carrillo Famés ,  Claudina Zaldivar Muñoz

IPC分类号： A61K39/00 ,  C12N15/09 ,  C07K7/06 ,  A23K1/18 ,  A61K38/25 ,  A61K38/08 ,  A23K1/165 ,  A23K1/16

CPC分类号： C07K7/06 ,  A23K20/147 ,  A23K20/168 ,  A23K20/184 ,  A23K50/80 ,  A61K38/08 ,  A61K38/25

摘要： The invention is related with the chemical synthesis for increase the growth rate in marketable fish and crustaceanThe aim of this invention is supply GHRP-6 to induce directly or indirectly the release of growthing hormone or like, to produce the increase of circulating growthing hormone level in the blood of the fishes. The peptide is stable, soluble and biologically active.The peptide is able to stimulate growth, improve the larvae quality, and increase the defense against pathogen agents, the dry weight, the protein concentration and the RNA in muscle of fish and crustaceans.

摘要翻译： 本发明涉及用于增加可销售鱼类和甲壳类动物生长速率的化学合成本发明的目的是提供GHRP-6直接或间接诱导生长激素等的释放，以产生循环生长激素水平的增加 在鱼的血中。 该肽是稳定的，可溶的和生物活性的。 该肽能够刺激生长，提高幼虫质量，增加对鱼和甲壳类动物肌肉的病原体，干重，蛋白质浓度和RNA的防御。

公开(公告)号：US20140294889A1

公开(公告)日：2014-10-02

申请号：US14238377

申请日：2012-08-24

申请人： Centro De Ingenieria Genetica y Biotecnologia

发明人： Juana Maria Lugo Gonzalez ,  Yamila Carpio Gonzalez ,  Mario Pablo Estrada Garcia

IPC分类号： A61K39/39

CPC分类号： A61K39/39 ,  A61K39/0003 ,  A61K39/002 ,  A61K39/0208 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55516 ,  A61K2039/55566 ,  A61K2039/6031 ,  C12N2720/10034 ,  C12N2760/20034 ,  C12N2770/24334

摘要： The present invention relates to the use of the pituitary adenylate cyclase activating peptide (PACAP) as a molecular adjuvant for vaccines. Among other applications, these vaccines may be used in the protection against infectious agents such as viruses, bacteria and ectoparasites affecting mammals, birds and aquatic organisms. The PACAP, combined with a particular antigen, demonstrates its effectiveness as adjuvant increasing the host immune response against that antigen. This type of response can be observed when the vaccine compositions or combinations that include PACAP are administered orally, by injection, or by immersion baths, in case of aquatic organisms.

摘要翻译： 本发明涉及垂体腺苷酸环化酶活化肽（PACAP）作为疫苗的分子佐剂的用途。 除其他应用之外，这些疫苗可用于防止感染性物质的侵害，例如影响哺乳动物，鸟类和水生生物的病毒，细菌和外寄生虫。 与特定抗原结合的PACAP证明其作为佐剂增加针对该抗原的宿主免疫应答的有效性。 当在水生生物的情况下，当疫苗组合物或包含PACAP的组合在口服，注射或浸浴中进行施用时，可以观察到这种类型的反应。

公开(公告)号：US08722742B2

公开(公告)日：2014-05-13

申请号：US12919416

申请日：2009-02-27

申请人： Yuliet Mazola Reyes ,  Glay Chinea Santiago ,  Osmany Guirola Cruz ,  Roberto Vera Alvarez ,  Vivian Huerta Galindo ,  Noralvis Fleitas Salazar ,  Alexis Musacchio Lasa

发明人： Yuliet Mazola Reyes ,  Glay Chinea Santiago ,  Osmany Guirola Cruz ,  Roberto Vera Alvarez ,  Vivian Huerta Galindo ,  Noralvis Fleitas Salazar ,  Alexis Musacchio Lasa

IPC分类号： A01N41/06 ,  A61K31/18 ,  A61K31/535 ,  A61K31/497 ,  A61K31/4965 ,  A01N43/40 ,  A61K31/445

CPC分类号： A61K31/16 ,  A61K31/18 ,  A61K31/381 ,  A61K31/41 ,  A61K31/426 ,  A61K31/428 ,  A61K31/44 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/506 ,  A61K31/535 ,  A61K31/55 ,  A61K47/54 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/395

摘要： Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.

摘要翻译： 使用在硅胶中获得的化学化合物用于制备药物组合物以减轻或抑制登革热病毒感染。 特别是通过与病毒进入宿主细胞相关的几个阶段的病毒复制循环的干扰或调节以及成熟后代病毒粒子的组装。 本发明还包括使用这种药物组合物预防和/或治疗由登革热病毒和其他黄病毒的四种血清型引起的感染。